These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21105857)

  • 1. Dapagliflozin: more than just another oral glucose-lowering agent?
    Katsiki N; Papanas N; Mikhailidis DP
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1581-9. PubMed ID: 21105857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Shah NK; Deeb WE; Choksi R; Epstein BJ
    Pharmacotherapy; 2012 Jan; 32(1):80-94. PubMed ID: 22392830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dapagliflozin on cardiovascular risk factors.
    Ptaszynska A; Hardy E; Johnsson E; Parikh S; List J
    Postgrad Med; 2013 May; 125(3):181-9. PubMed ID: 23748519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
    Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
    Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
    Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
    Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
    Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
    J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin: glucuretic action and beyond.
    Balakumar P; Sundram K; Dhanaraj SA
    Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
    Maranghi M; Carnovale A; Durante C; Tarquini G; Tiseo G; Filetti S
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):125-37. PubMed ID: 25418019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
    List JF; Woo V; Morales E; Tang W; Fiedorek FT
    Diabetes Care; 2009 Apr; 32(4):650-7. PubMed ID: 19114612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
    Merovci A; Mari A; Solis-Herrera C; Xiong J; Daniele G; Chavez-Velazquez A; Tripathy D; Urban McCarthy S; Abdul-Ghani M; DeFronzo RA
    J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
    Zhang L; Feng Y; List J; Kasichayanula S; Pfister M
    Diabetes Obes Metab; 2010 Jun; 12(6):510-6. PubMed ID: 20518806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary tract infections in patients with diabetes treated with dapagliflozin.
    Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
    J Diabetes Complications; 2013; 27(5):473-8. PubMed ID: 23849632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
    Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
    Musso G; Gambino R; Cassader M; Pagano G
    Ann Med; 2012 Jun; 44(4):375-93. PubMed ID: 21495788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.